Magazine Article | September 3, 2018

Novartis Turns To Digital Technologies For Clinical Trials

Source: Life Science Leader

By Ed Miseta, Chief Editor, Clinical Leader
Follow Me On Twitter @EdClinical

New and innovative technologies are making their way into clinical trials. But which have the greatest potential to transform studies?

"We are currently seeing emerging digital technologies which have an incredible potential to unlock the next chapter of medical innovation,” says Jake LaPorte, head of digital development for Novartis. “Artificial intelligence (AI) and the Internet of Things (IoT) are two disruptive but complementary technologies that are beginning to find broad applications, not just in pharma but in all of our society. They’re likely to have profound effects on the underpinnings of our economy and our society more broadly, much as the internet has.”